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The recent article in CMI by Ooesterheert et al.
[1] predicted a 23% increase in antibiotic use
following hypothetical implementation of the
British Thoracic Society (BTS) community-
acquired pneumonia (CAP) guidelines at a
teaching hospital in The Netherlands. We have
recently evaluated the implementation of a
management pathway to improve the time to
administration and the appropriateness of
empirical antibiotics for CAP at a UK teaching
hospital.
The intervention was based on the BTS
guidelines and emphasised the link between
severity assessment and appropriate antibiotic
Table 1. Characteristics of patients from whom colistin-resistant Gram-negative bacilli were isolated
Patient (month ⁄ year of
treatment ⁄diagnosis)
MIC of COL initially and COL
MIC during therapy
(day ⁄month of isolation)
Susceptibility
to other antibiotics
Pre-treatment
with other
antibiotics Outcome
Pt. 1 (12 ⁄ 2004–01 ⁄ 2005) Acinetobacter baumannii IMI, SUL, PIP ⁄TAZ CIP Recovered
Post-operative peritonitis MIC 8
Pt. 2 (04 ⁄ 2005–05 ⁄ 2005) Pseudomonas. aeruginosa Resistant to PIP ⁄TAZ, AMI, CIP, SUL Died
Pneumonia, peritonitis MIC 8 (8 ⁄ 4); MIC 8 (3 ⁄ 5) CTZ, MER, SUL, CIP PIP ⁄TAZ, CTZ
Pt. 3 (12 ⁄ 2004–02 ⁄ 2005) Citrobacter freundii Resistant to all antibiotics tested CIP, CTX Recovered
Septic shock MIC 0.25 (20 ⁄ 12); MIC 0.5 (22 ⁄ 12); MER, COL
Decubital ulcer MIC 4 (10 ⁄ 1); MIC 4 (18 ⁄ 1); MIC 8 (26 ⁄ 1)
Febrile neutropenia P. aeruginosa MIC 2 (21 ⁄ 12); Resistant to all antibiotics tested CIP, PIP ⁄TAZ
Nosocomial pneumonia MIC 4 (31 ⁄ 12); MIC 8 (4 ⁄ 1); MIC 4 (10 ⁄ 1); CEP, AMI
MIC 4 (17 ⁄ 1); MIC 4 (26 ⁄ 1); MIC 8 (31 ⁄ 1)
Escherichia coli MIC 8 (26 ⁄ 1)
Pt. 4 (08 ⁄ 2004–09 ⁄ 2004) Ps. aeruginosa MIC 8 (2 ⁄ 8); MIC 4 (16 ⁄ 8); Susceptible to AMI (MIC 16 mg ⁄L) CIP, TMZ, MER, Recovered
Pneumonia, peritonitis MIC 4 (3 ⁄ 9); MIC 8 (15 ⁄ 9) CTX, PIP ⁄TAZ
Klebsiella pneumoniae MIC 8 (2 ⁄ 8) Susceptible to AMI (8 mg ⁄L)
Acinetobacter spp. MIC 8 (15 ⁄ 9) Resistant to all antibiotics tested
Pt. 5 (03 ⁄ 2005) P. aeruginosa MIC 8 Resistant to all antibiotics tested CIP, MER Died
Peritonitis E. coli MIC 8
Pt. 6 (04 ⁄ 2005) K. pneumoniae MIC 64 Resistant to all antibiotics tested, COL, CIP Died
Liver abscess including MER, AMI, CIP, CTZ, PIP ⁄TAZ
Pt. 7 (05 ⁄ 2005) Stenotrophomonas maltophilia Susceptible to TMZ, CMP COL, PIP ⁄TAZ, Died
Peritonitis MIC 8 (17 ⁄ 5); MIC 8 (2 ⁄ 8); MIC 4 (16 ⁄ 8); CIP
MIC 4 (3 ⁄ 9); MIC 8 (15 ⁄ 9)
Pt. 8 (06 ⁄ 2005) S. maltophilia MIC 64 (3 ⁄ 6) Resistant to all antibiotics tested, COL, CIP, Died
P. aeruginosa MIC 64 (10 ⁄ 6) including CIP, TMZ, AMI PIP ⁄TAZ
Pt. 9 (06 ⁄ 2005) P. aeruginosa MIC 8 Resistant to all tested antibiotics COL, IMI Died
Peritonitis K. pneumoniae MIC 8
Pt. 10 (06 ⁄ 2005) K. pneumoniae MIC 8 Resistant to all tested antibiotics COL, CIP Died
Peritonitis P. aeruginosa MIC 8
COL, colistin; CMP, chloramphenicol; CIP, ciproﬂoxacin; SUL, cefoperazone ⁄ sulbactam; CTZ, ceftazidime; CEP, cefepime; CTX, cefotaxime; PIP ⁄TAZ, piperacillin ⁄ tazo-
bactam; MER, meropenem; TMZ, co-trimoxazole; AMI, amikacin; IMI, imipenem.
498 Clinical Microbiology and Infection, Volume 12 Number 5, May 2006
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12, 496–500
prescribing in CAP [2]. For patients with none
of the BTS-recommended adverse prognostic
indicators, home therapy with oral amoxycillin
was recommended (‘non-severe, home therapy’
group). For patients with one adverse prognostic
indicator, inpatient care with oral ⁄ intravenous
(IV) amoxycillin plus oral erythromycin or IV
clarithromycin was recommended (‘non-severe,
inpatient therapy’ group). For patients with
two or more adverse prognostic indicators,
IV co-amoxyclav plus IV clarithromycin was
recommended (‘severe’ group). Upgrading of
management was allowed if clinical judgement
suggested that this was required. The interven-
tion was implemented in October 2002 using
reminders, educational sessions, audit and feed-
back, and was evaluated using a controlled
before–after design.
At baseline (November 2001 to April 2002), the
proportion of patients in the non-severe, inpatient
therapy group who received amoxycillin plus a
macrolide was 49.5% (51 ⁄ 103) at the intervention
site and 69% (22 ⁄ 32) at the control site (differ-
ence = +19.5%; v2 3.64, p 0.06), compared with
21% (20 ⁄ 95) at the intervention site and 54%
(20 ⁄ 37) at the control site in the 6-month period
(November 2002 to April 2003) following
implementation (difference = )33%; v2 13.73,
p 0.0002%; difference in absolute change from
baseline = )13.5%). In contrast, the proportion of
patients receiving either co-amoxyclav ⁄ cefuroxi-
me ⁄ ceftriaxone plus a macrolide, or levoﬂoxacin
monotherapy, increased from 23.5% (24 ⁄ 103) to
62% (59 ⁄ 95) at the intervention site, and from
22% (7 ⁄ 32) to 32.5% (12 ⁄ 37) at the control site
(difference post-implementation = +29.5%; v2
9.43, p 0.002; difference in absolute change from
baseline = +28%). In the severe group, the
prescribing of amoxycillin plus a macrolide
decreased from 24% (17 ⁄ 71) to 6.5% (7 ⁄ 109) at
the intervention site, but increased from 14.5%
(4 ⁄ 28) to 41.5% (5 ⁄ 12) at the control site (differ-
ence post-implementation = )35%, p 0.004 (Fish-
er’s exact test); difference in absolute change from
baseline = +44.5%). In contrast, prescribing of
either co-amoxyclav ⁄ cefuroxime ⁄ ceftriaxone plus
a macrolide, or levoﬂoxacin monotherapy, in-
creased from 49.5% (35 ⁄ 71) to 83.5% (91 ⁄ 109) at
the intervention site, and from 35.5% (10 ⁄ 28) to
41.5% (5 ⁄ 12) at the control site (difference post-
implementation = +42%; p 0.006 (Fisher’s exact
test); difference in absolute change from base-
line = +28%). Overall, broad-spectrum antibiotic
prescribing increased from 42.5% to 77.5% at the
intervention site, but decreased from 45% to
41.5% at the control site (difference post-imple-
mentation = +36%, v2 26.21, p < 0.0001; unad-
justed difference in absolute change from
baseline = +38.5%; relative percentage change
post-implementation = +87%). There were no
signiﬁcant differences or trends towards improve-
ment in length of hospital stay or 30-day mortality
rates.
Before implementation, the mean cost of the
ﬁrst dose of antibiotic(s) prescribed was £6.34
(Euro 8.9) at the intervention site and £4.83 (Euro
6.8) at the control site (unadjusted difference
+£1.51 (Euro 2.1), 95% CI £0–3.03 (Euro 0–4.2),
p 0.05; adjusted difference (for severity) +£1.62
(Euro 2.3), 95% CI £0.02–3.21 (Euro 0.3–4.5),
p 0.05). Post-implementation, costs increased at
both sites to £9.01 (Euro 12.6) at the intervention
site and £6.42 (Euro 9.0) at the control site
(unadjusted difference +£2.59 (Euro 3.6), 95% CI
£1.02–4.16 (Euro 1.4–5.8), p 0.0001; adjusted
difference +£1.56 (Euro 2.2), 95% CI £0.01–3.12
(Euro 0.1–4.4), p 0.05; unadjusted difference
in absolute change from baseline = +£1.08 (Euro
1.5).
These results conﬁrm the prediction of Ooe-
sterheert et al. [1] that implementation of the BTS
CAP guidelines would increase broad-spectrum
antibiotic consumption. Although our interven-
tion reduced under-treatment of patients with
severe CAP signiﬁcantly, physicians appear to
have taken a ‘just in case’ approach for less
severe patients, which resulted in a signiﬁcant
increase in broad-spectrum prescribing for non-
severe CAP at the intervention site, probably
against a background of temporal trends at both
sites. This was despite the emphasis placed on
the link between severity assessment and appro-
priate antibiotic prescribing (both under- and
over-treatment) in the intervention. Although the
costs of the ﬁrst dose of antibiotic(s) did not
increase signiﬁcantly compared with the control
site, it is possible that the increase in broad-
spectrum prescribing may have impacted on
patient outcomes (e.g., by causing Clostridium
difﬁcile-associated diarrhoea or antibiotic-resist-
ant infections), thereby increasing costs indi-
rectly. An increase in adherence to the BTS
CAP guidelines has been suggested previously
as the cause of an increase in cephalosporin
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prescribing in a UK teaching hospital [3], which
resulted in an increase in the prevalence of
MRSA. In future, trials assessing clinical- and
cost-effectiveness of antibiotic guidelines should
measure and take account of such adverse
events.
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